Research output per year
Research output per year
Personal profile
Primary fields of research
Professor in Clinical cancer immune therapy and director of the translational research centre, Center for Cancer Immune Therapy (CCIT). CCIT is working translational and has a broad experience in preclinical as well as clinical research within cancer immunology and immunotherapy. Since 2005 CCIT has conducted numerous clinical trials including more than 200 cancer patients. It is an aim for CCIT to develop immunotherapeutic strategies for a broad spectrum of cancer diseases. Therefore, clinical trials have been carried out in diseases such as myeloma, melanoma, lung, -kidney, breast- and prostate cancer.
Current research
CCIT research includes e.g. more basic investigations on how the immune system reacts against cancer and which defect are involved in the sub-optimal function of the immune system leading to lack of cancer cell recognition and elimination.
Also, the research comprises clinical projects reaching from development and testing of peptide vaccines, dendritic cell based vaccines to T-cell therapy. The experimental treatments are frequently tested in combination with standard therapy such as chemotherapy with the intension of added efficacy.
Keywords
- Faculty of Health and Medical Sciences
- Immune therapy
- Melanoma
- T-cell therapy
- Cancer vaccines
- Dendritic cells
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
18F-FDG PET/CT assessment of metabolic tumor burden predicts survival in patients with metastatic posterior uveal melanoma
Hindso, T. G., Martinussen, T., Bjerrum, C. W., Keller, S. H., Loft, A., Sjøl, M. B., Nissen, K., Faber, C., Donia, M., Svane, I. M., Ellebaek, E., Heegaard, S., Kiilgaard, J. F. & Madsen, K., 2025, In: Scientific Reports. 15, 1, 13 p., 4110.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile8 Downloads (Pure) -
A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE)
Chen, I. M., Theile, S., Madsen, K., Johansen, J. S., Lorentzen, T., Toxværd, A., Høgdall, E., Svane, I. M. & Nielsen, D., 2025, In: Immuno-Oncology and Technology. 26, 7 p., 101054.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile -
The antitumor activity of TGFβ-specific T cells is dependent on IL-6 signaling
Perez-Penco, M., Byrdal, M., Lara de la Torre, L., Ballester, M., Khan, S., Siersbæk, M., Lecoq, I., Madsen, C. O., Kjeldsen, J. W., Svane, I. M., Hansen, M., Donia, M., Johansen, J. S., Olsen, L. R., Grøntved, L., Chen, I. M., Arnes, L., Holmström, M. O. & Andersen, M. H., 2025, In: Cellular and Molecular Immunology. 22, 1, p. 111-126 16 p., 104659.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile1 Citation (Scopus)18 Downloads (Pure) -
Transvitreal Retinochoroidal Biopsies of Primary Uveal Melanoma Reveal an Association of Low HLA Class I and High NK Cell Abundance in Low-Risk Disease
Bol, K. F., Sweep, M. W. D., Crowther, M. D., Gorris, M. A. J., Lara, P. A., Draghi, A., Bagger, M. M., Faber, C., Textor, J., Donia, M., Kiilgaard, J. F. & Svane, I. M., 2025, In: Investigative Ophthalmology and Visual Science. 66, 2, 12 p., 24.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile2 Downloads (Pure) -
Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab
Jensen, C., Maarup, S., Poulsen, H. S., Hasselbalch, B., Karsdal, M., Svane, I. M., Lassen, U. & Willumsen, N., 2024, (Accepted/In press) In: Clinical and Translational Oncology.Research output: Contribution to journal › Journal article › Research › peer-review
-
Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma
Monberg, T. J., Kudling, T., Albieri, B., Pakola, S., Ellebaek, E., Donia, M., Eefsen, R. L., von Buchwald, C., Kistler, C., Santos, J. M., Clubb, J., Haybout, L., Westergaard, M. C. W., Quixabeira, D. C. A., Jirovec, E., Havunen, R., Sorsa, S., Cervera-Carrascon, V., Hemminki, A. & Svane, I. M., 2024, In: Immuno-Oncology and Technology. 24, 10 p., 100726.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile1 Citation (Scopus)5 Downloads (Pure) -
Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis
Martín-Lluesma, S., Svane, I. M., Dafni, U., Vervita, K., Karlis, D., Dimopoulou, G., Tsourti, Z., Rohaan, M. W., Haanen, J. B. A. G. & Coukos, G., 2024, In: Annals of Oncology. 35, 10, p. 860-872 13 p.Research output: Contribution to journal › Review › peer-review
11 Citations (Scopus) -
Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study
Christensen, S. K., Winther, M. L., Laursen, I. J., Madsen, F. S., Brink, C., Brix, T. H., Ellebaek, E., Svane, I. M., Hansen, F. S., Haslund, C., Laursen, O. K., Schmidt, H., Larsen, I. D., Bastholt, L. & Ruhlmann, C. H., 2024, In: Supportive Care in Cancer. 32, 5, 10 p., 281.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile1 Citation (Scopus)5 Downloads (Pure)